Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Payables (2016 - 2025)

Regenxbio has reported Payables over the past 12 years, most recently at $21.4 million for Q4 2025.

  • Quarterly results put Payables at $21.4 million for Q4 2025, down 6.32% from a year ago — trailing twelve months through Dec 2025 was $21.4 million (down 6.32% YoY), and the annual figure for FY2025 was $21.4 million, down 6.32%.
  • Payables for Q4 2025 was $21.4 million at Regenxbio, down from $22.3 million in the prior quarter.
  • Over the last five years, Payables for RGNX hit a ceiling of $31.4 million in Q1 2024 and a floor of $9.4 million in Q2 2021.
  • Median Payables over the past 5 years was $21.5 million (2025), compared with a mean of $20.0 million.
  • Biggest five-year swings in Payables: skyrocketed 138.98% in 2022 and later crashed 39.27% in 2025.
  • Regenxbio's Payables stood at $11.4 million in 2021, then surged by 138.98% to $27.2 million in 2022, then dropped by 16.27% to $22.8 million in 2023, then grew by 0.05% to $22.8 million in 2024, then fell by 6.32% to $21.4 million in 2025.
  • The last three reported values for Payables were $21.4 million (Q4 2025), $22.3 million (Q3 2025), and $21.7 million (Q2 2025) per Business Quant data.